Invitrogen to use Genetix technology to screen cell clones

By Lisa Kerner

Charlotte, N.C., July 21 - Invitrogen Corp. entered into an agreement allowing the company to use Genetix Group plc's ClonePixFL technology to image, select and pick mammalian cell colonies based upon a variety of parameters.

The company will use the technology through PD-Direct, Invitrogen's integrated service that offers streamlined solutions for process development.

"The Genetix ClonePix technology greatly enhances our ability to rapidly screen clones for the highest producers," PD-Direct senior scientist Steve Feldman said in a company news release.

"Genetix has developed an excellent tool and we are excited to make this technology available to our process development clients."

Genetix, based in Hampshire, U.K., provides applications for cell biology, proteomic and genomic research.

Invitrogen is a Carlsbad, Calif.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.